Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer

2012 ◽  
Vol 14 (3) ◽  
pp. 252-260 ◽  
Author(s):  
Pei Zhang ◽  
Jinyan Wang ◽  
Danan Wang ◽  
Huan Wang ◽  
Fengping Shan ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Dendritic Cell ◽  
Tumor Immunity ◽  
Dendritic Cell Vaccine ◽  
Cell Vaccine

scholarly journals Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro

2014 ◽  
pp. 1389 ◽  
Author(s):  
Shuo Wang ◽  
Jing Liu ◽  
Shixiu Shao ◽  
Xianjun Li ◽  
Jiannan Gao ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Dendritic Cell ◽  
Dendritic Cell Vaccine ◽  
Cell Vaccine ◽  
Cancer Antigen

Enhanced anti-tumor immunity ex vivo induced by GM-CSF gene transducted dendritic cell vaccine

2011 ◽  
Vol 10 (3) ◽  
pp. 178-182 ◽  
Author(s):  
Songbing He ◽  
Liang Wang ◽  
Kang Sun ◽  
Yanyun Zhang ◽  
Dechun Li
Keyword(s):  
Dendritic Cell ◽  
Tumor Immunity ◽  
Ex Vivo ◽  
Dendritic Cell Vaccine ◽  
Cell Vaccine ◽  
Gm Csf

scholarly journals PATH-67. RECOMBINANT INTERLEUKIN-7 ENHANCES THE ANTI-TUMOR IMMUNITY OF A DENDRITIC CELL VACCINE IN A MURINE MALIGNANT GLIOMA

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi158-vi158
Author(s):  
Sol Hooy Oh ◽  
Stephen Ahn ◽  
Jae Sung Park ◽  
Yong Kil Hong ◽  
Sin-Soo Jeon
Keyword(s):  
T Cells ◽  
Dendritic Cell ◽  
Mouse Model ◽  
Malignant Glioma ◽  
Tumor Immunity ◽  
Dendritic Cell Vaccine ◽  
Cell Vaccine ◽  
Orthotopic Mouse Model ◽  
Interleukin 7 ◽  
Polycytidylic Acid

Abstract BACKGROUND Dendritic cell (DC)-based vaccines have been suggested as one of the promising immunotherapies for treating various cancers, including glioblastoma. We already developed a novel vaccination protocol with peptide-loaded DCs followed by a mixture of synthetic peptides, polyinosine- polycytidylic acid (poly-IC) and anti-CD40 antibodies (Trivax) in a melanoma mouse model. However, in a glioma mouse model, therapeutic efficacy is not as much as enough maybe due to relatively low antigenicity and blood brain barrier. MATERIAL AND METHODS IL-7, which is one of the most important cytokines to expand and develop T cells with anti-tumor immunity, was co-administrated intravenously with Trivax in an orthotopic murine malignant glioma. RESULTS Co-administration of the Trivax and recombinant IL-7 (Trivax7) increased the number of survivin specific T cells measured using ELISPOT assay and the population of central memory T cells, comparing with administration of Trivax. The tumor size of orthotopic mouse model in Trivax 7 group was smaller than those of Trivax only group. Finally, overall survival in Trivax 7 was longer than those of Trivax only. In addition, there was a prolonged survival of antigen-specific T cells in Trivax7 group than Trivax only group. CONCLUSION In summary, our novel combinational immunotherapy may overcome the limitations of current cell-based cancer vaccines and could be applicable for the treatment of glioblastoma patients.

Construction of PSA-specific dendritic cell vaccine and its in vitro immune activity

2009 ◽  
Vol 29 (3) ◽  
pp. 265-270
Author(s):  
Dan-feng XU ◽  
Yi GAO ◽  
Yu-shan LIU ◽  
Xin-gang CUI ◽  
Jian-ping CHE ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Dendritic Cell Vaccine ◽  
Cell Vaccine ◽  
Immune Activity

scholarly journals 423. The Combination of p53 Dendritic Cell Vaccine and Ad-p53 Gene Therapy Against p53 Overexpressing and p53 Deleted Tumor Cell Lines

2015 ◽  
Vol 23 ◽  
pp. S167
Author(s):  
Hiroki Saito ◽  
Koichi Kitagawa ◽  
Risa Yamasaki ◽  
Nami Katai ◽  
Naoya Morishita ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Dendritic Cell ◽  
Tumor Cell ◽  
Cell Lines ◽  
P53 Gene ◽  
Dendritic Cell Vaccine ◽  
Cell Vaccine ◽  
Tumor Cell Lines
Sign in / Sign up

Export Citation Format

Share Document